Previous 10 | Next 10 |
Gainers: ObsEva (OBSV) +56%, DBV Technologies (DBVT) +44%, Senseonics Holdings (SENS) +39%, Avinger (AVGR) +33%, Bionano Genomics (BNGO) +28%.Losers: Cardiff Oncology (CRDF) -20%, SOS (SOS) -18%, Lexicon Pharmaceuticals (LXRX) -11%,&...
SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. The three major U.S. stock averages ended Friday at all-time highs despite a weak December jobs report, in a session that zigzagged with the hopes of furth...
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced...
Gainers: Check-Cap (CHEK) +185%.Bionano Genomics (BNGO) +99%.The9 (NCTY) +92%.Ocugen (OCGN) +74%.Jaguar Health (JAGX) +42%.Pandion Therapeutics (PAND) +37%.ViewRay (VRAY) +33%.Bit Digital (BTBT) +29%.AirNet Technology (ANTE) +18%.Studio City International (MSC) +18%.Losers: ...
Calithera Biosciences (NASDAQ: CALA) , a clinical-stage biotech company, reported on Monday morning that telaglenastat, one of its leading pipeline candidates, flopped in a clinical trial. As a result, investors are selling-off shares of the company. As of 11:53 a.m. EST on Monday, ...
Calithera Biosciences (CALA) -56% as telaglenastat fails in kidney cancer study; lowers headcount.Genworth Financial (GNW) -29% after merger end-date passes.QuantumScape (QS) -18%.AeroCentury (ACY) -12%.FG Financial Group (FGF) -11%.Chindata Group Holdings (CD) -10%.PEDEVC...
Calithera Biosciences (CALA) plunges 35% in premarket in reaction to topline results from the CANTATA Phase 2 study evaluating its glutaminase inhibitor telaglenastat in combination with cabozantinib, in patients with advanced or metastatic renal cell carcinoma.The study failed to...
-- Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and emerging pipeline -- Company to host webcast and conference call today at 8:30 a.m. ET / 5:30 a.m. PT SOUTH SAN FRANCISCO, Calif.,...
Calithera has an important near-term catalyst that could launch the company into a significant commercialization opportunity by mid-year 2021. The company also is running a triplet therapy trial that if successful, would be the only treatment in a $10B market. Calithera is a high-...
News, Short Squeeze, Breakout and More Instantly...
Calithera Biosciences Inc. Company Name:
CALA Stock Symbol:
OTCMKTS Market:
Calithera Biosciences Inc. Website:
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...